Loading
A phase 3 trial of Etoposide, Carboplatin and Cisplatin in small-cell lung cancer, run by EpicentRx, Inc., active and no longer recruiting.
A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer is a phase 3 interventional study registered as NCT05566041 by EpicentRx, Inc., with 292 participants enrolled, started 2022-08-01 and due to reach its primary completion in 2025-12-31. Interventions recorded: RRx-001 + eLOOP Device and Cisplatin/carboplatin plus etoposide.
Shares EpicentRx and the tag pipeline.
Shares Etoposide, Cisplatin, Carboplatin and the tag pipeline.
Shares Etoposide, Cisplatin, Carboplatin, Small-cell lung cancer and the tag pipeline.
Shares Etoposide, Cisplatin, Small-cell lung cancer and the tag pipeline.
Shares Etoposide, Small-cell lung cancer and the tag pipeline.
Shares Etoposide, Cisplatin, Carboplatin and the tag pipeline.
Shares Cisplatin, Carboplatin and the tag pipeline.